IP Verse

In Vitro Glycoengineering Of Antibodies - EP3559248

The patent EP3559248 was granted to F Hoffmann LA Roche on Nov 20, 2024. The application was originally filed on Dec 19, 2017 under application number EP17829955A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3559248

F HOFFMANN LA ROCHE
Application Number
EP17829955A
Filing Date
Dec 19, 2017
Status
Patent Maintained As Amended
Oct 18, 2024
Grant Date
Nov 20, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MAIWALDAug 17, 2022MAIWALDADMISSIBLE

Patent Citations (66) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0307434
DESCRIPTIONUS2005079574
DESCRIPTIONUS2005119455
DESCRIPTIONUS2005260186
DESCRIPTIONUS2005266000
DESCRIPTIONUS2006025576
DESCRIPTIONUS2006057638
DESCRIPTIONUS2006104968
DESCRIPTIONUS2006127950
DESCRIPTIONUS2007061900
DESCRIPTIONUS2007117126
DESCRIPTIONUS2007160598
DESCRIPTIONUS2007237764
DESCRIPTIONUS2007292936
DESCRIPTIONUS2008069820
DESCRIPTIONUS2009002360
DESCRIPTIONUS4676980
DESCRIPTIONUS4816567
DESCRIPTIONUS5202238
DESCRIPTIONUS5204244
DESCRIPTIONUS5648237
DESCRIPTIONUS5731168
DESCRIPTIONUS5750373
DESCRIPTIONUS5770429
DESCRIPTIONUS5789199
DESCRIPTIONUS5821337
DESCRIPTIONUS5840523
DESCRIPTIONUS5959177
DESCRIPTIONUS6040498
DESCRIPTIONUS6075181
DESCRIPTIONUS6150584
DESCRIPTIONUS6171586
DESCRIPTIONUS6267958
DESCRIPTIONUS6417429
DESCRIPTIONUS6420548
DESCRIPTIONUS6982321
DESCRIPTIONUS7041870
DESCRIPTIONUS7087409
DESCRIPTIONUS7125978
DESCRIPTIONUS7189826
DESCRIPTIONUS7527791
DESCRIPTIONWO0034317
DESCRIPTIONWO2006029879
DESCRIPTIONWO2006044908
DESCRIPTIONWO2007131676
DESCRIPTIONWO2009080251
DESCRIPTIONWO2009080252
DESCRIPTIONWO2009080253
DESCRIPTIONWO2009080254
DESCRIPTIONWO2009089004
DESCRIPTIONWO2010112193
DESCRIPTIONWO2010115589
DESCRIPTIONWO2010136172
DESCRIPTIONWO2010145792
DESCRIPTIONWO2010145793
DESCRIPTIONWO2011012297
DESCRIPTIONWO2015123754
DESCRIPTIONWO2016037947
DESCRIPTIONWO9216640
DESCRIPTIONWO9308829
DESCRIPTIONWO9833523
DESCRIPTIONWO9852976
OPPOSITIONUS2011263828
OPPOSITIONWO2012037407
OPPOSITIONWO2015123754
OPPOSITIONWO2018114877

Non-Patent Literature (NPL) Citations (19) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Åkerström B, Björck L, "Protein L: An Immunoglobulin Light Chain-binding Bacterial Protein", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19891101), vol. 264, no. 33, doi:10.1016/S0021-9258(19)47174-3, ISSN 0021-9258, pages 19740 - 19746
OPPOSITION- Anonymous, "Capto™ L", GE Healthcare Bio-Sciences AB, (20120701), pages 1 - 8, GE Healthcare Bio-Sciences AB, (20220830), XP055956100
OPPOSITION- Anonymous, "Heavy-chain antibody", Wikipedia, the free encyclopedia, (20220614), Wikipedia, the free encyclopedia, URL: https://en.wikipedia.org/wiki/Heavy-chain_antibody#:~:text=A%20heavy%2Dchain%20antibody%20is,VH%20and%20VL)., (20220830), XP055956111
OPPOSITION- Anonymous, "Protein Handbook 2013", Life technologies, (20130101), pages 1 - 62
OPPOSITION- Anonymous, "Protein Handbook 2013", Life technologies, (20130101), pages 1 - 62, XP055956098
OPPOSITION- Anonymous, "Protein L", Wikipedia, the free encyclopedia, (20160605), Wikipedia, the free encyclopedia, URL: https://en.wikipedia.org/wiki/Protein_L, (20220830), XP055956104
OPPOSITION- Anonymous, "Protein L", Wikipedia, the free encyclopedia, (20220522), Wikipedia, the free encyclopedia, URL: https://en.wikipedia.org/wiki/Protein_L, (20220830), XP055956101
OPPOSITION- Barb Adam W., Meng Lu, Gao Zhongwei, Johnson Roy W., Moremen Kelley W., Prestegard James H., "NMR Characterization of Immunoglobulin G Fc Glycan Motion on Enzymatic Sialylation", Biochemistry, (20120605), vol. 51, no. 22, doi:10.1021/bi300319q, ISSN 0006-2960, pages 4618 - 4626
OPPOSITION- BOLT S., ET AL., "THE GENERATION OF A HUMANIZED, NON-MITOGENIC CD3 MONOCLONAL ANTIBODY WHICH RETAINS IN VIRTO IMMUNUSUPPRESSIVE PROPERTIES.", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (19930201), vol. 23., no. 02., doi:10.1002/eji.1830230216, ISSN 0014-2980, pages 403 - 410.
OPPOSITION- Castilho Alexandra, "Chapter 20", Castilho Alexandra, Castilho, Alexandra, Glyco-engineering : methods and protocols, US , New York, NY [u.a.] : Humana Pr. , (20150101), pages 287 - 305, ISBN 978-1-4939-2759-3
OPPOSITION- Castilho Alexandra, "Chapter 20", Castilho Alexandra, Castilho, Alexandra, Glyco-engineering : methods and protocols, US , New York, NY [u.a.] : Humana Pr. , (20150101), pages 287 - 305, ISBN 978-1-4939-2759-3, XP055956094
OPPOSITION- Frank Martin; Walker Ross C.; Lanzilotta William N.; Prestegard James H.; Barb Adam W., "Immunoglobulin G1 Fc Domain Motions: Implications for Fc Engineering", Journal of Molecular Biology, Academic Press, United Kingdom, United Kingdom , (20140209), vol. 426, no. 8, doi:10.1016/j.jmb.2014.01.011, ISSN 0022-2836, pages 1799 - 1811
OPPOSITION- MALIK ET AL, "In vitro glycoengineering - suitability for BioPharma manufacturing", ROCHE, Application Note, (20160401), pages 1 - 8, ROCHE, Penzberg Company information, URL: http://custombiotech.roche.com/content/dam/internet/dia/custombiotech/custombiotech_com/en_GB/pdf/CustomBiotech_Glycoengineering_ApplicationNote.pdf, (20180302), XP002778746
OPPOSITION- Malik Sebastian, Grunert Ingrid, Von Roman Matthias Freiherr, Walch Heiko, Dams Thomas, Thomann Marco, Falkenstein Roberto, "Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production", GLYCOBIOLOGY, Oxford University Press, US, US , (20220319), vol. 32, no. 2, doi:10.1093/glycob/cwab109, ISSN 0959-6658, pages 123 - 135
OPPOSITION- BOLT S., ET AL., "THE GENERATION OF A HUMANIZED, NON-MITOGENIC CD3 MONOCLONAL ANTIBODY WHICH RETAINS IN VIRTO IMMUNUSUPPRESSIVE PROPERTIES.", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (19930201), vol. 23., no. 02., doi:10.1002/eji.1830230216, ISSN 0014-2980, pages 403 - 410., XP000561698
OPPOSITION- Frank Martin; Walker Ross C.; Lanzilotta William N.; Prestegard James H.; Barb Adam W., "Immunoglobulin G1 Fc Domain Motions: Implications for Fc Engineering", Journal of Molecular Biology, Academic Press, United Kingdom, United Kingdom , (20140209), vol. 426, no. 8, doi:10.1016/j.jmb.2014.01.011, ISSN 0022-2836, pages 1799 - 1811, XP028832571
OPPOSITION- Åkerström B, Björck L, "Protein L: An Immunoglobulin Light Chain-binding Bacterial Protein", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19891101), vol. 264, no. 33, doi:10.1016/S0021-9258(19)47174-3, ISSN 0021-9258, pages 19740 - 19746, XP055956087
OPPOSITION- Barb Adam W., Meng Lu, Gao Zhongwei, Johnson Roy W., Moremen Kelley W., Prestegard James H., "NMR Characterization of Immunoglobulin G Fc Glycan Motion on Enzymatic Sialylation", Biochemistry, (20120605), vol. 51, no. 22, doi:10.1021/bi300319q, ISSN 0006-2960, pages 4618 - 4626, XP055956085
OPPOSITION- Malik Sebastian, Grunert Ingrid, Von Roman Matthias Freiherr, Walch Heiko, Dams Thomas, Thomann Marco, Falkenstein Roberto, "Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production", GLYCOBIOLOGY, Oxford University Press, US, US , (20220319), vol. 32, no. 2, doi:10.1093/glycob/cwab109, ISSN 0959-6658, pages 123 - 135, XP055956090

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents